Heparin-induced thrombocytopenia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Heparin-induced thrombocytopenia}} {{CMG}}; '''Associate Editor(s)-In-Chief:''' Priyamvada Singh, M.B.B.S. [mailto:psingh@perfuse.org] ==Overview== [[He...")
 
No edit summary
Line 5: Line 5:


==Epidemiology and demographics==
==Epidemiology and demographics==
* [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
* Mortality rate can be as high as 20%
* 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)


===United States of America===
===United States of America===
* Incidences varies from 1-5%.
* Incidences varies from 1-5%.
===Race===
===Race===
Line 14: Line 16:
Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia  
Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia  
===Age===
===Age===
Risks for development of HIT Increases with increased age (>60years)  
Risks for development of HIT Increases with increased age (>60years)
 
==Reference==
==Reference==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 12:34, 10 December 2011

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia epidemiology and demographics

CDC on Heparin-induced thrombocytopenia epidemiology and demographics

Heparin-induced thrombocytopenia epidemiology and demographics in the news

Blogs on Heparin-induced thrombocytopenia epidemiology and demographics

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

Overview

Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of platelet and endothelium.

Epidemiology and demographics

  • Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
  • Mortality rate can be as high as 20%
  • 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)

United States of America

  • Incidences varies from 1-5%.

Race

Some studies have shown that the incidences of heparin-induced thrombocytopenia (HIT) are more common among white patients compare to non-white population.

Sex

Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia

Age

Risks for development of HIT Increases with increased age (>60years)

Reference